{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:59:24Z","timestamp":1774616364387,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T00:00:00Z","timestamp":1376265600000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.bjid.2012.12.005","type":"journal-article","created":{"date-parts":[[2013,7,10]],"date-time":"2013-07-10T13:45:19Z","timestamp":1373463919000},"page":"418-426","source":"Crossref","is-referenced-by-count":15,"title":["Economic evaluation of treatments for chronic hepatitis B"],"prefix":"10.1016","volume":"17","author":[{"given":"Astrid","family":"Wiens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Venson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L\u00facia Alves","family":"Pedroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2012.12.005_bib0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3748\/wjg.15.423","article-title":"DNA-guided hepatitis B treatment, viral load is essential, but not sufficient","volume":"15","author":"Barcena Marugan","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bjid.2012.12.005_bib0010","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3949\/ccjm.75a.07019","article-title":"Hepatitis B virus infection: understanding its epidemiology, course, and diagnosis","volume":"75","author":"Elgouhari","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2893.2009.01078.x","article-title":"Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides","volume":"16","author":"Nguyen","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bjid.2012.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.bjid.2012.12.005_bib0025","series-title":"Decision making in health and medicine: integrating the evidence and values","author":"Hunink","year":"2001"},{"key":"10.1016\/j.bjid.2012.12.005_bib0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/135965350701200308","article-title":"Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial","volume":"12","author":"Chan","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2012.12.005_bib0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0040","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjid.2012.12.005_bib0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir","volume":"49","author":"Leung","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2012.12.005_bib0050","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0055","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0060","first-page":"71","article-title":"Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B","volume":"25","author":"Ayaz","year":"2006","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.bjid.2012.12.005_bib0065","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bjid.2012.12.005_bib0070","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1086\/375085","article-title":"Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B","volume":"36","author":"Yalcin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2012.12.005_bib0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0168-8278(01)00145-3","article-title":"Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial","volume":"35","author":"Barbaro","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2012.12.005_bib0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7326\/0003-4819-142-4-200502150-00006","article-title":"A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone","volume":"142","author":"Chan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0085","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial","volume":"47","author":"Hou","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2012.12.005_bib0100","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0105","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3851\/IMP1466","article-title":"A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B","volume":"14","author":"Piccolo","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2012.12.005_bib0110","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1128\/AAC.00088-07","article-title":"Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B","volume":"51","author":"Kaymakoglu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2012.12.005_bib0115","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0120","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0125","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.3748\/wjg.v11.i37.5882","article-title":"Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B","volume":"11","author":"Economou","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bjid.2012.12.005_bib0130","first-page":"CR56","article-title":"Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study","volume":"15","author":"Papadopoulos","year":"2009","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.bjid.2012.12.005_bib0135","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2007.12.026","article-title":"Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B","volume":"48","author":"Sung","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2012.12.005_bib0140","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2893.2005.00566.x","article-title":"Lamivudine vs lamivudine and interferon combination treatment of HBeAg(\u2212) chronic hepatitis B","volume":"12","author":"Yurdaydin","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bjid.2012.12.005_bib0145","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-147-11-200712040-00183","article-title":"Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial","volume":"147","author":"Chan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0150","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy","year":"2008","journal-title":"Value Health"},{"issue":"Suppl. 5","key":"10.1016\/j.bjid.2012.12.005_bib0155","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1002\/hep.22884","article-title":"Hepatitis B virus DNA levels and outcomes in chronic hepatitis B","volume":"49","author":"Chen","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2012.12.005_bib0160","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjid.2012.12.005_bib0165","doi-asserted-by":"crossref","first-page":"821","DOI":"10.7326\/0003-4819-142-10-200505170-00007","article-title":"Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis","volume":"142","author":"Kanwal","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bjid.2012.12.005_bib0170","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00019053-200826110-00006","article-title":"A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B","volume":"26","author":"Spackman","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.bjid.2012.12.005_bib0175","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1365-2036.2008.03691.x","article-title":"Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis","volume":"27","author":"Veenstra","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bjid.2012.12.005_bib0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1524-4733.2007.00221.x","article-title":"HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan","volume":"11","author":"Veenstra","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.bjid.2012.12.005_bib0185","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1524-4733.2010.00733.x","article-title":"Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis","volume":"13","author":"Wu","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.bjid.2012.12.005_bib0190","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bjid.2012.12.005_bib0195","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1590\/S0104-42302007000600013","article-title":"Cost estimates of chronic hepatitis B virus for the Brazilian unified health system in 2005","volume":"53","author":"Castelo","year":"2007","journal-title":"Rev Assoc Med Bras"},{"issue":"Suppl 1","key":"10.1016\/j.bjid.2012.12.005_bib0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2010.02387.x","article-title":"Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues","volume":"31","author":"Leung","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.bjid.2012.12.005_bib0205","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1440-1746.2008.05455.x","article-title":"Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients","volume":"23","author":"Suzuki","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bjid.2012.12.005_bib0210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12072-008-9049-2","article-title":"The economics of treating chronic hepatitis B in Asia","volume":"2","author":"Dan","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bjid.2012.12.005_bib0215","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1590\/S1413-86702008000500005","article-title":"Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil","volume":"12","author":"Costa","year":"2008","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.bjid.2012.12.005_bib0220","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2009.04.013","article-title":"Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B","volume":"51","author":"Buti","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2012.12.005_bib0225","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/medicina46120117","article-title":"Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania","volume":"46","author":"Vanagas","year":"2010","journal-title":"Medicina (Kaunas)"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867013001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867013001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T01:52:57Z","timestamp":1688349177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867013001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1413867013001025"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2012.12.005","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}